| 摘要 |
The present invention is directed to a pharmaceutical composition compris ed of one or more SGLT-2 inhibitor compound(s) in combination with one or mo re therapeutic agents which is suitable for the treatment of metabolic disor ders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, ob esity, including class I obesity, class II obesity, class III obesity, visce ral obesity and abdominal obesity, and metabolic syndrome. |
